Evidence map›Paper›PMID 35271592›Full record

SynthesisPloS one2022

Therapeutic efficacy of artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine in the treatment of uncomplicated Plasmodium falciparum malaria in Sub-Saharan Africa: A systematic review and meta-analysis.

Karol Marwa, Anthony Kapesa, Vito Baraka, Evelyne Konje, Benson Kidenya, Jackson Mukonzo, Erasmus Kamugisha, Gote Swedberg

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in PloS one, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed, 4 pooled it
12.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 4 syntheses or guidelines pooled it, 63 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 3 countries.

Karol MarwaDepartment of Pharmacology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.ORCID 0000-0001-5237-2904
Anthony KapesaDepartment of Community Medicine, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Vito BarakaNational Institute for Medical Research, Tanga Centre, Tanga, Tanzania.
Evelyne KonjeDepartment of Epidemiology, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Benson KidenyaDepartment of Biochemistry, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Jackson MukonzoDepartment of Pharmacology and Therapeutics, Makerere University, Kampala, Uganda.
Erasmus KamugishaDepartment of Biochemistry, Catholic University of Health and Allied Sciences, Mwanza, Tanzania.
Gote SwedbergDepartment of Medical Biochemistry and Microbiology, Uppsala University, Uppsala, Sweden.
Catholic University of Health and Allied Sciences · TZMakerere University · UGNational Institute for Medical Research · TZUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSub-Saharan Africa has the highest burden of malaria in the world. Artemisinin-based combination therapies (ACTs) have been the cornerstone in the efforts to reduce the global burden of malaria. In the effort to facilitate early detection of resistance for artemisinin derivatives and partner drugs, WHO recommends monitoring of ACT's efficacy in the malaria endemic countries. The present systematic meta-analysis study summarises the evidence of therapeutic efficacy of the commonly used artemisinin-based combinations for the treatment of uncomplicated P. falciparum malaria in Sub-Saharan Africa after more than a decade since the introduction of the drugs.

methodsFifty two studies carried out from 2010 to 2020 on the efficacy of artemether-lumefantrine or dihydro-artemisinin piperaquine or artesunate amodiaquine in patients with uncomplicated P. falciparum malaria in Sub-Saharan Africa were searched for using the Google Scholar, Cochrane Central Register of controlled trials (CENTRAL), PubMed, Medline, LILACS, and EMBASE online data bases. Data was extracted by two independent reviewers. Random analysis effect was performed in STATA 13. Heterogeneity was established using I2 statistics.

resultsBased on per protocol analysis, unadjusted cure rates in malaria infected patients treated with artemether-lumefantrine (ALU), artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DHP) were 89%, 94% and 91% respectively. However, the cure rates after PCR correction were 98% for ALU, 99% for ASAQ and 99% for DHP.

conclusionThe present meta-analysis reports the overall high malaria treatment success for artemether-lumefantrine, artesunate-amodiaquine and dihydroartemisinin-piperaquine above the WHO threshold value in Sub-Saharan Africa.

Indexed as

AntimalarialsMalariaMalaria, FalciparumAfrica South of the SaharaAmodiaquineArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsArtesunateDrug CombinationsEthanolaminesHumansPiperazinesPlasmodium falciparumQuinolinesAmodiaquineAntimalarialsArtemetherArtemether, Lumefantrine Drug CombinationArtemisininsartenimolArtesunateDrug CombinationsEthanolaminespiperaquinePiperazinesQuinolines

Identifiers

PMID35271592
PMCPMC8912261
OpenAlexW4221008337

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.